Skip to content
+49 40 3009799 0 order@oncoscience.de
EnglishEnglish
  • DeutschDeutsch
Oncoscience
  • COMPANY
  • ONCOLOGY
  • PRODUCT
  • RESEARCHExpand
    • CLINICAL TRIALS
    • PUBLICATIONS
  • FAQ
  • NEWS
+49 40 3009799 0 
EnglishEnglish
  • DeutschDeutsch
Oncoscience
NEWS

Oncoscience AG announces final results of a phase-II study in pediatric patients with recurrent high-grade malignant glioma treated with the monoclonal antibody NIMOTUZUMAB directed against EGF-R, as monotherapy

ByOncoscience 8. June 2007

Read More Oncoscience AG announces final results of a phase-II study in pediatric patients with recurrent high-grade malignant glioma treated with the monoclonal antibody NIMOTUZUMAB directed against EGF-R, as monotherapyContinue

Oncoscience GmbH
Osterbrooksweg 59
22869 Schenefeld
Germany

 

Phone: +49-40 300 9799-0
Fax: +49-40 300 9799-20
Email: order@oncoscience.de

part of

Legal Notice

© 2025 Oncoscience

Scroll to top
  • COMPANY
  • ONCOLOGY
  • PRODUCT
  • RESEARCH
    • CLINICAL TRIALS
    • PUBLICATIONS
  • FAQ
  • NEWS
Search
Diese Website benutzt Cookies. Wenn du die Website weiter nutzt, gehen wir von deinem Einverständnis aus.OKDatenschutzerklärung